In an increasingly digital age, most companies are inviting public comments on social media sites, and using this as a way to gauge engagement with the brand. But pharmaceutical companies are not.
In August 2011, when Facebook stopped giving the option to turn off public comments, many pharmaceutical companies shut down their Facebook pages. These companies cited a lack of guidance from the Food and Drug Administration (FDA) on how they should handle the comments.
The FDA has a prescription. On Wednesday, the FDA released draft social media guidelines for how pharmaceutical companies respond to consumer comments online. The guidelines urge companies not to respond to unsolicited requests for information in a public forum. Instead, companies should respond by guiding the requestor to the appropriate department for private help.
For most, these guidelines aren’t enough for them to get back on Facebook. They are concerned and unclear if they could be liable for information posted by third parties, specifically information related to adverse drug events.
Kudos to these pharma companies for thinking beyond the present moment, and considering the long-term effect missteps due to unclear guidance could have on their brand equity.
The FDA is accepting public comments on the guidance through March 26.
What are your thoughts?